Navigation Links
InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
Date:6/29/2010

LOS ALTOS, Calif., June 29 /PRNewswire/ -- InteKrin Therapeutics presented 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® (pioglitazone), yesterday at the American Diabetes Association annual meeting in Orlando, FL.

INT131 besylate (INT131) is a novel, non-TZD, selective oral PPAR-gamma modulator (SPPARM) designed to improve glucose metabolism while minimizing the side effects of the TZD full PPAR-gamma agonists such as Actos®: fluid retention (edema), CHF, bone fracture, and weight gain. The Phase 2b trial, INT131-007, was a 366 patient 24 wk double blind study comparing 4 doses of INT131 to maximal dose Actos® (pioglitazone) or placebo in patients with poorly controlled T2DM on stable dose sulfonylurea (SU) with or without metformin (met). Lower extremity edema was assessed with a predefined scoring tool designed for maximal sensitivity for pitting edema at baseline, 12, and 24 wks. Results show INT131 improved glycemic control as measured by HbA1c comparable to Actos® but without evidence of any significant change in edema compared to baseline or placebo. Substantial edema was noted in the pioglitazone group, consistent with published data. These findings support the SPPARM function of INT131 and suggest it represents a safer insulin sensitizer.

"This data clearly differentiates INT131 besylate from pioglitazone with respect to the important clinical parameter of edema," remarked Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, who presented the data. "These findings are consistent with previous clinical data and support the advantages of the SPPARM nature of this agent."

"Insulin
'/>"/>

SOURCE InteKrin Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... leading retail drugstore chain in China ... today announced the appointment of Ms. Rebecca Yingnan ... immediately. Ms.Zhang has over 20 years ... in March 1999. Prior to Ms. Zhang,s appointment as ...
(Date:11/24/2014)... Juno Therapeutics today announced that the ... company,s JCAR015 chimeric antigen receptor product candidate.  The ... refractory B-cell acute lymphoblastic leukemia and was filed ... Center, where Phase 1 clinical trials are currently ... important news for patients who may benefit from ...
(Date:11/24/2014)... YORK , Nov. 24, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... to present at the LD MICRO "MAIN Event" Micro-Cap ... will be held at the Luxe Sunset Bel Air ... Los Angeles, California . ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... NEW YORK, Dec. 6, 2010 Keryx Biopharmaceuticals, ... data presented for the first time at the ... Hematology showing promising clinical activity, safety and tolerability ... leukemia (CLL) and Hodgkin,s lymphoma (HL).  KRX-0401 (perifosine) ...
... L.P. unveiled an enhanced version of its popular educational ... easier for healthcare professionals, people with pain and their ... tools. For more than 17 years, the Partners Against ... the quality of pain management for individuals touched by ...
Cached Medicine Technology:Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 2Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 3Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 4Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma 5Purdue Pharma L.P. Re-launches Partners Against Pain Website 2
(Date:11/26/2014)... (PRWEB) November 26, 2014 Louisiana ... relief and specialists in minimally invasive spine surgery, ... Shamieh into the rapidly growing provider network of ... The addition coincides with the network’s continuing success ... treatment for Louisiana residents who are suffering from ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... Nov. 25, 2014 (HealthDay News) -- Youngsters who enter ... new study suggests. Early puberty was linked with ... poor self-image and high anxiety levels, according to the ... such as conflict with family and peers, and having ... study found. Although the study found an association ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Teens prescribed anti-anxiety ... abuse those drugs than other teens, a new ... to conduct substance abuse assessments on teenagers before ... "Prescribers and parents don,t realize the abuse ... at the University of Michigan School of Nursing. ...
(Date:11/26/2014)... Exposure to peanut protein in household dust may increase ... skin condition eczema, a new study reveals. About ... are allergic to peanuts. And severe eczema in infants ... the researchers noted. The new study included 359 ... examined the amount of peanut protein the children were ...
Breaking Medicine News(10 mins):Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Infants With Eczema May Be More Prone to Peanut Allergy: Study 2
... three-dimensional image of the AIDS virus, with lots of protein ... immune cells – An extraordinary work since past 25 year ... AIDS research could boost the development of vaccines that will ... proteins. In fact, said principal investigator and FSU Professor Kenneth ...
... found that daily intake of alcohol may reduce the risk ... the research has concluded that it is applicable only for ... raises important questions about drinking patterns and heart health among ... should be interpreted with caution and should not be used ...
... over 3500 and an incalculable number of people injured after ... cope with the injured and the dead. ,The quake ... city of Yogyakarta which is near the southern coast of ... left the city in shambles, cutting off communications and road ...
... British Pregnancy Advisory Service (BPAS) has announced that nearly a ... nine weeks of pregnancy had involved// the abortion pill, also ... figures reveal that the demand for the abortion pill in ... women undergoing the procedure last year.,BPAS said the number of ...
... Ashodya Mahila Samanwayas Samithi (AMSS), is launching a smart and ... ,As many as 500 sex workers are set ... first time in the country this scheme is to start ... cards. The smart card project, the brainchild of Karnataka Health ...
... green substance inside the body of a lobster commonly known ... by may others as a waste//, unhealthy product. The health ... against eating too much of lobster tomalley. ,The ... serve as a liver and pancreas for lobster, can sometimes ...
Cached Medicine News:Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 2Health News:Three-Dimensional Image Of AIDS Virus – BY FSU Researcher 3Health News:Daily Intake Of Alcohol Reduces Heart Disease In Men Than Women 2Health News:Indonesian Earthquake – Story of Destruction, Death and Disease 2Health News:Record Number Of Women Use Abortion Pills 2Health News:Sex Workers To Have Smart Health Card 2
Used to introduce balloon, diagnostic and guiding catheters, or other devices for intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Medicine Products: